#USA #Veeva Systems #San Rafael #BioMarin #Therapy Development

Strategic Partnership between Veeva and BioMarin

In a significant development within the biopharmaceutical industry, Veeva Systems and BioMarin Pharmaceutical Inc. have formed a long-term enterprise agreement that aims to enhance the operational efficiencies and speed of drug development processes. This partnership builds on an established relationship between the two companies and is intended to optimize both the healthcare professionals' and patients' experiences through advanced software, data solutions, services, and consulting products.

Enhancing Drug Development

BioMarin, recognized for its innovations in treating rare genetic diseases, expressed enthusiasm about the partnership, stating, "This strategic partnership marks an important next step in our digital evolution." Alexander Hardy, the President and CEO of BioMarin, articulated a vision of merging their scientific know-how with Veeva's technological prowess to expedite the delivery of transformative medicines to patients worldwide.

By leveraging Veeva's comprehensive suite of cloud-based solutions, BioMarin anticipates an acceleration in the integration of industry-leading approaches within their operations. This endeavor aligns with BioMarin's commitment to unlock the potential of genetic science and deliver impactful treatments more effectively to patients.

The Veeva Advantage

Peter Gassner, Veeva's CEO, reflected on the partnership, emphasizing the shared values that underpin their collaboration: commitment to product excellence, realization of value, and achieving customer success. Underpinning this foundation, Gassner expressed optimism regarding how both companies could enhance their joint efforts in advancing critical medicines that could benefit more patients globally.

Veeva Systems provides specialized solutions targeted at the life sciences sector. Their offerings include cutting-edge software platforms designed for the industry's unique challenges, facilitating greater efficiency and better patient outcomes. As they broaden their collaboration with BioMarin, both companies aim to foster innovation that bridges the gap between scientific advancement and patient access to new therapies.

About BioMarin

Founded in 1997 and based in San Rafael, California, BioMarin is a global pioneer in biotechnology focusing on developing medicines for genetically defined conditions. The company boasts a robust portfolio of commercial therapies alongside a promising pipeline of clinical and preclinical candidates that exemplify their distinctive approach to drug discovery. BioMarin seeks to harness genetic science's transformative potential to create innovative therapies that leave a lasting impact on patients' lives.

About Veeva Systems

Veeva has positioned itself as the industry cloud leader for life sciences by offering software solutions, data insights, and consulting services. Serving over 1,500 customers including the largest biopharmaceutical firms and emerging biotech companies, Veeva's commitment to innovation is coupled with a focus on balancing stakeholder interests, aiming to create value for customers, employees, and the industries it serves. Their goals promise to take life sciences into a new digital era.

Conclusion

The long-term partnership between Veeva Systems and BioMarin Pharmaceutical Inc. marks a crucial step in harnessing technology for healthcare advancements. As these two industry leaders combine their strengths, the collaboration is poised to transform how therapies are developed and delivered, with significant implications for patients who rely on innovative treatments for rare genetic diseases. For ongoing updates and news, visit BioMarin’s official website and Veeva’s official site.